Internal Medicine, Pulmonary Disease · Dallas, TX
NPI
1467610667
Since 2008
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
5323 Harry Hines Blvd
Dallas, TX, 75390
Phone (214) 645-2800
Groups this clinician bills Medicare through
Medicare paid, 2024
$38K
423 services
Medicare patients, 2024
109
Average age 65
Drug cost, 2024
$3.1M
476 prescriptions
Company payments, 2025
$107
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James D Finklea Jr. was code 99233 (hospital e&m - subsequent), 178 times for 59 patients. In total James D Finklea Jr. billed 423 services in 22 codes, and Medicare paid $38K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 178 | 59 | $90.90 | $16K |
| 94010 Pulmonary Function Testing | Office | 59 | 18 | $19.19 | $1,132 |
| 99214 Office E&M - Established | Office | 50 | 19 | $86.83 | $4,341 |
| 99291 Critical Care E&M | Facility | 44 | 26 | $163.65 | $7,201 |
| 99223 Hospital E&M - Initial | Facility | 36 | 35 | $133.64 | $4,811 |
By year: 2022 $41K for 464 services; 2023 $34K for 381 services; 2024 $38K for 423 services.
Medicare prescription drug claims, 2024
In 2024, the drug James D Finklea Jr. prescribed most often to Medicare patients was Trikafta (Elexacaftor/Tezacaftor/Ivacaft), with 71 prescriptions and refills. In total James D Finklea Jr. wrote 476 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trikafta Elexacaftor/Tezacaftor/Ivacaft | 71 | 72 | 14 | $1.9M |
| Creon Lipase/Protease/Amylase | 53 | 60 | 12 | $157K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 38 | 48 | 12 | $1,355 |
| Kalydeco Ivacaftor | 27 | 27 | Under 11 | $763K |
| Levalbuterol Tartrate Hfa Levalbuterol Tartrate | 23 | 28 | Under 11 | $1,416 |
| Fluticasone Propionate Generic | 22 | 25 | Under 11 | $231 |
| Azithromycin Generic | 16 | 26 | Under 11 | $169 |
| Zenpep Lipase/Protease/Amylase | 13 | 22 | Under 11 | $107K |
| Breo Ellipta Fluticasone/Vilanterol | 13 | 13 | Under 11 | $5,136 |
| Doxycycline Monohydrate Generic | 12 | 12 | Under 11 | $312 |
| Ciprofloxacin Hcl Generic | 11 | 11 | Under 11 | $145 |
Brand drugs: 285 claims; generic drugs: 191 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James D Finklea Jr. $107 ($107 in general payments such as food, travel and fees) from 5 companies. The largest payer was Merck Sharp & Dohme LLC with $32.86.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.